Company: DMAAR
Filing Date: 2025-01-14
Form Type: POS AM
Source: 0001213900-25-003137
Chunk: 203

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-14
Form: POS AM
Chunk 203
---
 PRIVATE UNITS Our sponsor has committed to purchase an aggregate of 400,000 private units (or 430,000 private units if the underwriters’ option to purchase additional units is exercised in full) at a price of $10.00 per unit ($4,000,000 in the aggregate, or $4,300,000 in the aggregate if the underwriters’ option to purchase additional units is exercised in full) in a private placement that will occur simultaneously with the closing of this offering. If we do not complete our initial business combination within the completion window, the proceeds of the sale of the private units held in the trust account will be used to fund the redemption of our public shares, and the private units will be worthless. The private units are identical to the units sold in this offering, except that they (including underlying securities) are entitled to registration rights, as described below. Our sponsor has the option to extend the completion window up to two times, each by an additional three months (for a total of up to 21 months to complete an initial business combination from the closing of this offering) by depositing into the trust account $0.10 per public share outstanding in connection with each such extension.

128 The non -managingsponsor investors have indicated an interest to indirectly purchase, through the purchase of non -managingsponsor membership interests, an aggregate of 50,000 of the 400,000 private placement units (or 430,000 private placement units if the underwriters’ over -allotmentoption is exercised in full) being purchased by our sponsor at a price of $10.00 per unit ($500,000 in the aggregate) in a private placement that will close simultaneously with the closing of this offering. Subject to each non -managingsponsor investor purchasing, through the sponsor, the private placement units allocated to it in connection with the closing of this offering, the sponsor will issue membership interests at a nominal purchase price to the non -managingsponsor investors reflecting interests in an aggregate of 666,667 founder shares held by the sponsor. Our initial shareholders and our directors and officers are deemed to be our “promoters” as such term is defined under the federal securities laws. See “ Certain Relationships and Related Party Transactions” for additional information regarding our relationships with our promoters. EXPRESSION OF INTEREST The non -managingsponsor investors have expressed to us an interest in purchasing up to an aggregate of approximately $39.8million of the units in this offering at the offering